Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM001 long-term safety extension study in Alagille syndrome or PFIC
2015-000906-20Phase 2Terminated
- Sponsor
- Takeda
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of maralixibat in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) (2 arms), sponsored by Takeda. Primary endpoints: Durability of therapeutic effect on serum laboratory markers of cholestasis and Long-term safety of LUM001. Started Apr 2015; status: terminated.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on 2015-000906-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000906-20.